Scott T. Tagawa, MD, highlights new data on urothelial carcinoma presented at ASCO 2024, including research showing that starting with a higher dose of enfortumab vedotin improves response rates, whereas dose reductions and delays are effective for managing toxicity without affecting efficacy. Additional data on this agent from the EV-302 study provided informative long-term patient-reported outcomes.
Further results confirmed that gemcitabine-cisplatin plus nivolumab outperforms gemcitabine-cisplatin alone, especially in patients with lymph node–only disease. Dr Tagawa states that even though there were no dramatic breakthroughs, the updated data offer valuable insights into optimizing current treatments and managing side effects.
